(Q35915813)

11 August 2017

1 reference

title

Benefit of extended zoledronate therapy for patients with bone metastases from hormone-refractory prostate cancer (English)

1 reference

11 August 2017

Nancy Price

1

1 reference

11 August 2017

publication date

1 September 2004

1 reference

11 August 2017

published in

Clinical prostate cancer

1 reference

11 August 2017

volume

3

1 reference

11 August 2017

issue

2

1 reference

11 August 2017

page(s)

77-79

1 reference

Morphometric evidence for bone resorption and replacement in prostate cancer

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1540-0352%2811%2970065-8

7 January 2021

Biology of osteoclast activation in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1540-0352%2811%2970065-8

7 January 2021

Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation

1 reference

https://api.crossref.org/works/10.1016%2FS1540-0352%2811%2970065-8

7 January 2021

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1540-0352%2811%2970065-8

7 January 2021

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1540-0352%2811%2970065-8

7 January 2021

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1540-0352%2811%2970065-8

7 January 2021

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1540-0352%2811%2970065-8

7 January 2021

10.1016/S1540-0352(11)70065-8

Identifiers

DOI

0 references

1 reference